Table 1

Demographic characteristics of 42 spondyloarthritis patients

Characteristic

Total (42 patients)

Without ADA (31 patients)

With ADA (11 patients)

p value


Sex, male

23 (54.8%)

16 (51.6%)

7 (63.6%)

0.726

Age

49.60 ± 10.46

51.26 ± 10.08

44.91 ± 10.53

0.084

HLA-B27-positivea

23/36 (64%)

17/27 (63%)

6/9 (66.7%)

0.841

Disease duration (years)

12.24 ± 8.23

11.61 ± 8.04

14 ± 8.92

0.416

Baseline ASDAS

3.42 ± 1.01

3.52 ± 1.03

3.14 ± 0.95

0.399

Concomitant treatment

Methotrexate

9 (21.5%)

8 (25.8%)

1 (9.1%)

0.498

Other DMARDs

10 (23.8%)

5 (16.1%)

5 (45.4%)

0.115

Methotrexate + other

1 (4,7%)

2 (6.4%)

0 (0%)

0.599

DMARDs

Monotherapy

21 (50%)

16 (51.7%)

5 (45.5%)

0.126

Corticosteroid therapy

15 (35.7%)

9 (29%)

6 (50%)


Data presented as n (%) or mean ± standard deviation. ADA, anti-drug antibodies; ASDAS, Ankylosing Spondylitis Disease Activity Score; DMARD, disease-modifying anti-rheumatic drug. an/total number (%).

Plasencia et al. Arthritis Research & Therapy 2013 15:R79   doi:10.1186/ar4258

Open Data